-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In multiple studies of patients treated with immune checkpoint inhibitors (ICI), the occurrence of treatment-related adverse events (trAE) is closely related to clinical outcomes; but whether this relationship exists in patients with hepatocellular carcinoma (HCC) Not sure
immunity
This study aims to explore the correlation between adverse events related to ICI treatment and the clinical prognosis of HCC patients
We included 406 patients with unresectable or advanced HCC who were treated with ICI
In this study cohort, did trAE2 affect OS and PFS?
In this study cohort, did trAE2 affect OS and PFS?Among these 406 patients, 325 (80%) Barcelona clinical liver cancer (BCLC) stage C HCC patients mostly received ICI monotherapy (n=258, 64%), of which 228 (56.
The occurrence of trAE2 was associated with longer OS (16.
In the multi-institution cohort, is there any effect of trAE2 on OS and PFS?
In the multi-institution cohort, is there any effect of trAE2 on OS and PFS?In a multi-institution cohort of 357 patients with similar characteristics, most patients also received ICI monotherapy (n=304, 85%)
The occurrence of trAE2 is longer related to OS (23.
The occurrence of trAE2 is related to the improvement of the prognosis of HCC patients receiving ICI treatment in clinical trials and clinical practice.
Original source:
Pinato David J,Marron Thomas U,Mishra-Kalyani Pallavi Shruti et al.
Related-toxicity and Improved Treatment outcome in hepatocellular from Cancer Immunotherapy: AN Evidence from the FDA
in this message